DK1432446T3 - Fremgangsmåder til identifikation af polypeptidantigener forbundet med lidelser som involverer afvigende celleproliferation - Google Patents

Fremgangsmåder til identifikation af polypeptidantigener forbundet med lidelser som involverer afvigende celleproliferation

Info

Publication number
DK1432446T3
DK1432446T3 DK02797854.3T DK02797854T DK1432446T3 DK 1432446 T3 DK1432446 T3 DK 1432446T3 DK 02797854 T DK02797854 T DK 02797854T DK 1432446 T3 DK1432446 T3 DK 1432446T3
Authority
DK
Denmark
Prior art keywords
methods
antibodies
mitotic
polypeptide antigens
cell proliferation
Prior art date
Application number
DK02797854.3T
Other languages
English (en)
Inventor
Arthur D Levinson
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1432446T3 publication Critical patent/DK1432446T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02797854.3T 2001-09-05 2002-09-04 Fremgangsmåder til identifikation af polypeptidantigener forbundet med lidelser som involverer afvigende celleproliferation DK1432446T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31750401P 2001-09-05 2001-09-05
PCT/US2002/028176 WO2003020909A2 (en) 2001-09-05 2002-09-04 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders

Publications (1)

Publication Number Publication Date
DK1432446T3 true DK1432446T3 (da) 2011-07-18

Family

ID=23233944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02797854.3T DK1432446T3 (da) 2001-09-05 2002-09-04 Fremgangsmåder til identifikation af polypeptidantigener forbundet med lidelser som involverer afvigende celleproliferation

Country Status (17)

Country Link
EP (1) EP1432446B1 (da)
JP (2) JP5224632B2 (da)
KR (3) KR20090104925A (da)
CN (2) CN1578673A (da)
AT (1) ATE506965T1 (da)
AU (1) AU2002332838B2 (da)
BR (1) BR0212641A (da)
CA (1) CA2457541C (da)
DE (1) DE60239881D1 (da)
DK (1) DK1432446T3 (da)
HU (1) HUP0500617A3 (da)
IL (2) IL160659A0 (da)
MX (1) MXPA04002084A (da)
NZ (1) NZ531515A (da)
PL (1) PL374363A1 (da)
WO (1) WO2003020909A2 (da)
ZA (1) ZA200401751B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL3524611T3 (pl) * 2003-05-20 2021-06-14 Immunogen, Inc. Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NO347360B1 (no) * 2003-10-10 2023-09-25 Immunogen Inc Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse.
CN107325182A (zh) * 2008-04-02 2017-11-07 宏观基因有限公司 HER2/neu‑特异性抗体和其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
WO2000052054A2 (en) * 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
AU778199B2 (en) * 1999-10-29 2004-11-25 Genentech Inc. Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use
WO2001055720A2 (en) * 2000-01-26 2001-08-02 Ventana Medical Systems, Inc. A system for developing assays for personalized medicine

Also Published As

Publication number Publication date
CN1578673A (zh) 2005-02-09
EP1432446A2 (en) 2004-06-30
AU2002332838B2 (en) 2007-08-02
WO2003020909A3 (en) 2003-11-20
HUP0500617A3 (en) 2012-05-02
KR20040044850A (ko) 2004-05-31
CA2457541C (en) 2013-01-08
PL374363A1 (pl) 2005-10-17
EP1432446B1 (en) 2011-04-27
HUP0500617A2 (hu) 2005-10-28
EP1432446A4 (en) 2004-09-08
WO2003020909A2 (en) 2003-03-13
CA2457541A1 (en) 2003-03-13
JP2010280691A (ja) 2010-12-16
IL160659A0 (en) 2004-08-31
NZ531515A (en) 2007-11-30
MXPA04002084A (es) 2004-06-07
BR0212641A (pt) 2005-04-12
JP2005517155A (ja) 2005-06-09
ZA200401751B (en) 2005-07-27
JP5224632B2 (ja) 2013-07-03
DE60239881D1 (de) 2011-06-09
ATE506965T1 (de) 2011-05-15
IL160659A (en) 2011-07-31
KR20090104925A (ko) 2009-10-06
CN101446590A (zh) 2009-06-03
KR20100061863A (ko) 2010-06-09

Similar Documents

Publication Publication Date Title
WO2020236817A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
IL181473A (en) Antibodies @ people @ against @@@ beta @@ preparations that include them and use them
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
IL214325A (en) Antibody against cmet, a drug that includes and uses it
BRPI0607203A2 (pt) anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
WO2008019025A3 (en) Isoform-selective hdac inhibitors
BG106738A (en) A method for chemoprevention of prostate cancer
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
WO2008091620A3 (en) Combination therapy comprising romidepsin and i.a. bortezomib
WO2024077023A3 (en) Cereblon-recruiting bcl-xl/bcl-2 dual degraders
AU2002352708A1 (en) Cytotoxic agents
WO2004089294A3 (en) Compositions, methods and kits relating to her-2 cleavage
MX2024013871A (es) Agentes aglutinantes 5t4 y usos de los mismos
DK1432446T3 (da) Fremgangsmåder til identifikation af polypeptidantigener forbundet med lidelser som involverer afvigende celleproliferation
TW200619848A (en) Photoresist compositions
PL1732926T3 (pl) Inhibitory kinezyn motorycznych